A graduate of Brooklyn College, Edgar Alacan served as a private jet coordinator before launching Jets.com in 2008 and growing it to a $40 million business. Outside of his leadership role with Jets.com, Edgar Alacan gives back to the community through his work on the board of directors for nonprofit groups such as Pietro’s Fight.
Founded by Dayna and Manni Scarso, Pietro’s Fight was established and is named after the Scarsos’ son, Pietro, who was diagnosed at the age of three with Duchenne muscular dystrophy (DMD). The organization holds events throughout the year to raise awareness for this rare genetic condition and to generate funds for innovative therapies that hold promise for what is currently considered an incurable disease.
Over the years, Pietro’s Fight has supported several initiatives that have led to promising new breakthroughs in the treatment of DMD. In 2015 and 2016, the organization threw its support behind the experimental drug Eteplirsen after Pietro participated in a trial for the new medication. Seeing positive results from the therapy, Pietro’s Fight raised more than $1 million to support a campaign to get the drug approved by the FDA.
In the fall of 2016, the FDA announced it had approved Eteplirsen for the treatment of DMD, bringing new hope to thousands of young boys afflicted with the disease around the country. Researchers say that the drug approval will also encourage further research into innovative therapies for the condition.
Founded by Dayna and Manni Scarso, Pietro’s Fight was established and is named after the Scarsos’ son, Pietro, who was diagnosed at the age of three with Duchenne muscular dystrophy (DMD). The organization holds events throughout the year to raise awareness for this rare genetic condition and to generate funds for innovative therapies that hold promise for what is currently considered an incurable disease.
Over the years, Pietro’s Fight has supported several initiatives that have led to promising new breakthroughs in the treatment of DMD. In 2015 and 2016, the organization threw its support behind the experimental drug Eteplirsen after Pietro participated in a trial for the new medication. Seeing positive results from the therapy, Pietro’s Fight raised more than $1 million to support a campaign to get the drug approved by the FDA.
In the fall of 2016, the FDA announced it had approved Eteplirsen for the treatment of DMD, bringing new hope to thousands of young boys afflicted with the disease around the country. Researchers say that the drug approval will also encourage further research into innovative therapies for the condition.
